CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors, today announced the appointment of Lisa Butterfield to its Scientific Advisory Board (SAB). A highly respected leader in immuno-oncology, Dr. Butterfield brings extensive expertise in cancer vaccines, immune profiling, biomarker development and cellular therapies for solid tumor types. Her appointment comes as Epitopea advances its pipeline of RNA-based cancer immunotherapies, including its lead candidate CryptiVax™-1001, for high-grade serous ovarian cancer.